Equine Healthcare Market Forecast 2013 - 2019

The global equine healthcare market was valued at USD 26.6 billion in 2012 and is expected to decline at a CAGR of -1.2% from 2013 to 2019, to reach an estimated value of USD 24.5 billion in 2019.

Browse the full report with complete TOC at Equine Healthcare Market http://www.transparencymarketresearch.com/equine-healthcare-market.html

The equestrian industry results in a substantially high economic impact as a result of one of the industry's primary activity - horse racing and betting; horse racing and betting comprises ~20% share of the global betting/gambling market. The equestrian industry thus generates a multiplier effect resulting into turnover of over ~USD 500 billion per year. Due to the 'trickle-down effect' of flow of the economic impact of the overall equestrian industry, multiple support or secondary markets exist and sustain; the equine healthcare market is among such support or secondary markets. As the base of existence of the equestrian industry is the population/number of horses worldwide, any change in the equine population impacts the equestrian industry and the support or secondary markets such as the equine healthcare market. Many experts and corroborating statistical data reveals that the global equine population is expected to decline over the years till 2019; consequentially, the equine healthcare market too is expected to decline by 1.2% over six years, from 2013 to 2019, to reach an estimated value of USD 24,527.8 million in 2019.

Equine healthcare market comprises of various 'product market segments' in context of various products used for treatment of equine-specific healthcare conditions, diagnosis of equine-specific healthcare conditions and also supplements and protection products used for upkeep and maintenance of a horse.Thus the three prime segments of the equine healthcare market are equine diagnostic products, equine therapeutic products and equine supplement products.

Request for customization of this report http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1603

In context of equine (pregnancy and gestation) diagnostic products, there are two key categories of products used namely UltraSound devices and equine urine test kits. Of the two categories, equine urine test kits are affordable and easy-to-use and interpret the results and also help overcome a prime limitation of UltraSound devices i.e. the kits are non-invasive in nature. Thus, we expect equine urine test kits to be increasingly preferred by the veterinarians and the end-users, going forward. Also, the equine urine test kit is a unique product to the equine species and cannot be substituted by the urine test kits for humans. Therefore, we estimate the urine test kits market to be a niche opportunity that is likely to be encashed by newer entrants thus expanding the market and driving growth of the equine diagnostic products market.

Browse all Press Releases: http://www.transparencymarketresearch.com/press-releases.htm

In terms of geographical markets of the equine healthcare market, the Asia-Pacific region is touted to be the 'next growth story'. A constituent of Asia-Pacific namely the Australian market is among the leading 'horse producing/breeding' countries. Additionally, China is expanding capacity and investing in horse racing and betting by importing quality breeds from other countries. China is thus intent on maintaining particularly race-horse breeds. As race-horses require additional and specific supplement and protection products, therapeutic and also diagnostic products, sales of all these products is thus expected to be high in the Asia-Pacific market. Therefore the afore-mentioned factors are likely to drive growth of the Asia-Pacific market.

Browse all Article : http://www.transparencymarketresearch.com/articles.htm

Theglobal equine healthcaremarket is segmented as follows:

Equine Diagnostic Products Market, by Type

• Equine Pregnancy and Gestation Diagnostic Products Market
• Equine Genotype Analysis Products Market

Equine Therapeutics Product Market, by Type

• Equine Vaccines Market
• Equine Antibacterials Market
• Equine Antivirals Market
• Equine Antiprotozoals/Dewormers Market
• Equine Dopamine Agonists Market
• Equine Anti-inflammatory Drugs Market
• Equine Laxatives Market

Equine Supplement Products Market, by Type

• Equine Performance Supplement Market
• Equine Protection Products Market
• Equine Prosthetics Market

Equine HealthcareMarket, by Geography

• North America
• Europe
• Asia-Pacific
• Rest of World (RoW)

Browse all Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Sheela AK

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Web: http://www.transparencymarketresearch.com/

Blog: http://www.tmrblog.com/

Erectile Dysfunction Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

The global erectile dysfunction drugs market was valued at USD 4.3 billion in 2012 and is expected to decline at a CAGR of (4.5%) from 2013 to 2019, to reach an estimated value of USD 3.4 billion in 2019.

Browse the full report with complete TOC at Erectile Dysfunction Drugs Market http://www.transparencymarketresearch.com/erectile-dysfunction-drugs.html

Erectile dysfunction is the inability to attain or maintain penile erection in men, sufficient for successful sexual intercourse. Erectile dysfunction is a common medical disorder primarily affecting men older than 40 years of age. In addition, other than the typical causes of erectile dysfunction, such as diabetes and hypertension, a number of common lifestyle related factors are also associated with development of the condition. These include obesity, excessive alcohol consumption, smoking, use of recreational drugs, and poor physical and psychological health. Commonly, oral drugs belonging to the PDE 5 inhibitors class form the mainstay of erectile dysfunction treatment. Other treatment options include lifestyle modification, testosterone therapy, penile devices, injection therapies and psychotherapy.

The global market for erectile dysfunction drugs has been studied from the perspective of currently marketed branded drugs and pipeline drugs. Branded drugs include Viagra (sildenafil citrate), Cialis (tadalafil), Levitra/Staxyn (vardenafil), Stendra/Spedra (avanafil), Zydena (udenafil), MUSE (medicated urethral systems for erection), Mvix (mirodenafil) and Helleva (lodenafil). The drugs in the pipeline for erectile dysfunction treatment primarily consist of two major drugs, namely Vitaros (alprostadil) and Uprima (apomorphine) currently in later phases of clinical trials.

In 2012, Viagra (sildenafil citrate) accounted for the largest share (45%) by revenue of the total erectile dysfunction drugs market. However, due to the loss of the drug's patent exclusivity in Europe and other countries in 2013, the overall market revenue is expected to decline during the forecast period as international markets contribute considerably to the overall market revenue of the drug. In the U.S. market, Viagra will continue to maintain a major revenue share due to its extended patent exclusivity till 2020. The market for Cialis (tadalafil) accounted for the second largest share at USD 1,926.8 million, in 2012. However, it is expected to witness a decline in market revenue at a CAGR of (12.6%) from 2013 to 2019, owing to loss of patent exclusivity in 2017. In addition, the patent for Bayer's Levitra/Staxyn (vardenafil) is scheduled to expire in 2018 and is thus expected to contribute to the declining market revenue.

Request for customization of this report http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1550

A few novel compounds are currently under investigation in both preclinical and clinical settings, for the treatment of impotency. These studies are majorly focused on medications with improved efficacy, shorter onset of action and fewer side effects as compared to the currently available treatments. Such pipeline drugs include Vitaros (alprostadil), Uprima (apomorphine) and Topiglan (alprostadil), amongst others.

Geographically, North America dominated the global market for erectile dysfunction drugs in terms of revenue generation and is expected to maintain its position throughout the forecast period. The extended patent exclusivity for Pfizer's Viagra (sildenafil citrate) in the U.S., till 2020, will be responsible for the leadership of the North American market. Europe was the second largest regional market for erectile dysfunction drugs in 2012, owing to the increased demand for ED drugs. Market growth will also be facilitated by the expected marketing approvals for a few promising drug candidates such as Stendra/Spedra (avanafil) and Zydena (udenafil) by mid 2014.

Browse all Press Releases: http://www.transparencymarketresearch.com/press-releases.htm

The global erectile dysfunction dugs market is dominated by few major players including Pfizer, Inc. Eli Lilly & Co., and Bayer AG. Post patent expiration of the major branded drugs and intense genericization of the market, the competition in this market is expected to be characterized by consolidation activities, partnerships, and intensive mergers and acquisitions. The other key players in the erectile dysfunction drugs market include Dong-A Pharmaceutical Co. Ltd., Vivus, Inc., Apricus Biosciences, Inc. and Meda Pharmaceuticals.

Browse all Article : http://www.transparencymarketresearch.com/articles.htm

The global erectile dysfunction drugs market is segmented as follows:

Erectile Dysfunction Drugs Market, by Major Branded Products

• Viagra
• Cialis
• Levitra/Staxyn
• Stendra/Spedra
• Zydena
• MUSE
• Mvix
• Helleva

Erectile Dysfunction Drugs Market, Pipeline Analysis

• Vitaros
• Uprima
• Others
• Topiglan
• Melanocortin Activators
• Gene Therapy

Erectile Dysfunction Drugs Market, by Geography

• North America
• Europe
• Asia-Pacific
• Rest of the World (RoW)

Browse all Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Sheela AK

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Web: http://www.transparencymarketresearch.com/

Blog: http://www.tmrblog.com/

Meningococcal Vaccines Market Expected to Reach USD 3.76 Billion Globally in 2019

The market for meningococcal vaccines was valued at USD 1.5 billion in 2012 and is expected to reach a value of USD 3.7 billion in 2019, growing at a CAGR of 14.9% from 2013 to 2019.

Browse Meningococcal Vaccines Market Report With Full TOC http://www.transparencymarketresearch.com/meningococcal-vaccines-market.html

Meningococcal disease is caused by the bacterium Neisseria meningitidis and occurs sporadically throughout the world with seasonal variations. It accounts for a proportion of endemic bacterial meningitis, which can progress very rapidly leading to death within 24 hours from the onset of symptoms. The disease is often misinterpreted as common flu in most of the cases. Five out of the several serogroups are known to cause meningococcal disease. These serogroups responsible for the disease comprises serogroups A, B, C, Y and W-135. The causative agent N. meningitidis is commonly found in the nasopharynx of humans and gets transmitted through droplet inhalation by means of close contact such as exposure to smokers, crowded living conditions such as dormitories, certain inherited disorders of the immune system, functional/anatomical asplenia or though intimate oral contact among others. According to European Federation of Pharmaceutical Industries and Association every year meningitis affects almost 5 lakh people globally, primarily affecting toddlers, infants and young adults, due to weaker immune system.

The global market for meningococcal vaccines is segmented broadly into vaccine types namely, polysaccharide, conjugate and combination vaccines. The report also provides analysis for vaccines under development that are expected to be commercialized during the forecast period 2013 to 2019. The vaccine types are further segmented by different brands available in the market. The conjugate vaccines segment is likely to lead the overall meningococcal vaccines market in terms of revenue, which is estimated to reach approximately USD 2.5 billion by 2019 at a CAGR of 12.9%. Amongst the pipeline vaccines, Novartis's Bexsero is expected to grow at the fastest rate of 24.7% during the forecast period 2013 to 2019. According to Department of Health, U.K., Bexsero is the first serogroup B vaccine to be incorporated into the national immunization program and is expected to be available in the market for sales by the second quarter of 2014. The MnB rLP2086 vaccine from Pfizer is currently in phase III clinical trials and has been granted with Breakthrough Therapy status by U.S. FDA in 2014.

Request for customization of this report http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1666

Geographically, North America lead the global meningococcal vaccines market in 2012 due to government interventions, wider immunization programs, and favorable research and development initiative by manufacturers. According to National Meningitis Association of the U.S., about 20 percent of all meningococcal disease cases occur in teens and young adults aged 14 years to 24 years. As per the Centers for Disease Control and Prevention (CDC) 1,000 to 2,600 people contract meningitis annually in the U.S. Meningococcal vaccines licensed in the U.S. are only against A, C, Y and W-135 serogroups and not against serogroup B. The use of Bexsero as an Investigational New Drug (IND) in combating the disease during the outbreaks in Princeton University and University of California, Santa Barbara in 2013, is likely to clear the way for Bexsero's approval in the U.S. market sooner than expected. This region is followed by Rest of the World comprising the Latin American countries, the Middle East and African countries. This has been attributed to the high incidence rate of meningococcal diseases in this region. Europe accounts for the lowest CAGR due to rise free sales of the vaccines especially meningococcal C vaccines.

Browse All Market Research Reports: http://www.transparencymarketresearch.com/categories.html

By 2019, Asia-Pacific is estimated to be the fastest growing regional market with a CAGR of around 17.1%. Major drivers for this market include low cost of manufacturing and transfer of novel technologies with respect to vaccine manufacturing, from developed parts of the world to the emerging economies. Advancements in manufacturing technology have been helping companies in manufacturing novel products that are not only affordable in developing and underprivileged nations, but are also comparable in terms of quality to their high-end alternatives.

Browse Market Research Articles: http://www.transparencymarketresearch.com/articles.htm

The global market for meningococcal vaccines is largely driven by increasing government intervention in reforming the healthcare infrastructure and incorporation of legislations specific to meningococcal vaccination. The public-private partnerships for conducting research and development, and manufacturing of quality vaccines at an affordable price are also contributing positively in driving market growth. Awareness campaigning from government and non-profit organizations and obligatory immunization for individuals heading to Mecca (for Hajj pilgrimage) and the South African meningitis belt will also contribute to growth of this market. High cost of few but vital vaccines, such as Bexsero, and need for efficient cold chain logistics to maintain safety and efficacy of the vaccine are expected to be some of the major factors posing a challenge to the adequate uptake of these vaccines.

Browse all Press Releases: http://www.transparencymarketresearch.com/press-releases.htm

The key players dominating in the global meningococcal vaccines include Sanofi Pasteur (the vaccine division of Sanofi SA), Novartis International AG and GSK plc. These players account for more than 80% of the meningococcal vaccines market. Players such as Serum Institute of India Ltd., JN International Medical Corporation, Biomed Pvt. Ltd., Nuron Biotech and Baxter account for the remaining market share.

Browse all Article : http://www.transparencymarketresearch.com/articles.htm

The global meningococcal vaccines market is segmented as follow:

Meningococcal Vaccines Market, by Type

Polysaccharide Vaccines, by Brand

Menomune

Mencevax

NmVac4

Others

Quadri Meningo

Bi Meningo

Conjugate Vaccines, by Brand

Menactra

Menveo

NeisVac-C

Nimenrix

Meningitec

Menjugate

MenAfriVac

Combination Vaccines, by Brand

MenHibrix

Menitorix

Pipeline Vaccines, by Brand

Bexsero

MnB rLP2806

NmVac4-DT

Meningococcal Vaccines Market, by Geography

North America

Europe

Asia-Pacific

Rest of the World

Browse Pharmaceutical Market Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Ms. Sheela AK

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Catheters Market Will Reach USD 33.3 Billion Globally in 2017

Global catheters market was worth USD 20.4 billion in 2011 and is further expected to reach USD 33.3 billion in 2017, growing at a CAGR of 8.5% from 2011 to 2017. The cardiovascular catheter was the largest market segment at USD 8.3 billion in 2011. Globally, North America was the largest regional market with 44.3% share in 2011; however European region is expected to take the lead position post 2016.

Browse the full report at Catheters Market http://www.transparencymarketresearch.com/catheters-market.html

The global catheters market is expected to reach USD 22.6 billion in 2012. Aging population in both developed and emerging markets, patient's choice for minimally invasive procedures, and product innovations are key growth drivers for the market. The catheter devices market is segmented into cardiovascular, specialty, urological, neurovascular, and intravenous catheters. Among all types of catheters, cardiovascular catheters account for about 40.9% of the global catheter market.

This report analyzes the worldwide market for catheters for the period of 2010 to 2017. The in-depth research and high level analysis will allow catheters product manufacturers, service providers, marketing companies, research and development agencies to make informed decisions about catheters manufacturing, marketing, growth strategies and gaining competitive advantage.

Request for customization of this report http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=109

Geographies Covered

North America

Europe

Asia-Pacific

China

Rest of the World (RoW)

Browse all Press Releases: http://www.transparencymarketresearch.com/press-releases.htm

Catheters Segments Covered

Cardiovascular

Neurovascular

Intravenous

Urological

Specialty

Browse all Article : http://www.transparencymarketresearch.com/articles.htm

Reasons to purchase this report

This research is specially designed to estimate and analyze the demand and performance of the global and China catheters market. The report covers all the major segments of catheters market and provides in-depth analysis, market revenue, and trend analysis by segments and statistically refined forecast for the segments covered. The report also provides:

Definition, estimates & forecast for the global and China catheters market from 2010 to 2017

Market forces driving and restraining the growth of the market

Up-to-date analysis of the latest trends in the industry

Leading industry opinion keeps you abreast of latest news and trends

Forward-looking outlook on a category, market or issue affecting the industry

Make more informed business decisions from insightful and in-depth analysis of the market performance

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Sheela AK

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Smoking Cessation and Nicotine De-addiction Products Market Trends 2013 - 2019

The global smoking cessation and nicotine de-addiction productsmarket was valued at USD 5.1 billion in 2012 and is expected to grow at a CAGR of 18.7% from 2013 to 2019, to reach an estimated value of USD 16.02billion in 2019.

Smoking cessation is a process of discontinuing smoking achieved by the use of medication. It may also be coupled with assistance of healthcare professionals, counselling and psychotherapy. The demand for smoking cessation products is high and is continuously rising as it caters to the needs of people addicted to nicotine and rising healthcare awareness amongst the smokers. The global smoking cessation and nicotine de-addiction products market is segmented on the basis of product types available in the market. These include nicotine replacement therapy (NRT) products, drug therapy and e-cigarettes. This market is sustained by large number of people wanting to quit smoking.

Browse Global Smoking Cessation and Nicotine De-addiction Products Market Report with Full TOC at http://www.transparencymarketresearch.com/smoking-cessation-nicotine-de-addiction-products.html

NRT products for smoking cessation include nicotine containing gums, patches, lozenges, sublingual tablets, inhalers and mouth sprays. The market for NRT products is dominated by the revenue of nicotine gums, patches and lozenges. Nicotine gums are one of the most widely used NRT products, and the market for these was valued at USD 995.5 million in 2012. The nicotine patches and lozenges market is driven by its ease of use and non-prescription sale. Nicotine sprays and inhalers on the other hand are less preferred due to their high cost and less popularity. However, increased promotional activities and effective distribution is expected to boost their market growth in the near future. The major players in the NRT products market include Johnson and Johnson, GSK, Cipla and Novartis.

Smoking cessation drug therapy market is expected to witness a decline in revenue across the globe, by the end of the forecast period due to patent expiration of the key revenue generating drugs Zyban (bupropion) in 2013 and Chantix/Champix (varenicline) in 2018 (which will impede market growth toa lower extent). The loss of patent and marketing exclusivity will lead to a drastic reduction in revenue and in turn provide an opportunity to generic manufacturers to launch their own versions of these brands. The leading players in the drug therapy market are GSK and Pfizer.

The e-cigarettes segment is expected to witness the fastest growth, and thus, will boost growth of the global smoking cessation and nicotine de-addiction products market during the forecast period. E-cigarettes have proved to be a better alternative to cigarettes whose smoke contains various harmful gases and cause dreadful diseases such as cancer. With the exceptional growth and popularity among the younger population, the market has posed a challenge to other smoking cessation products as well as to the tobacco cigarette business. The global e-cigarettes market was worth USD 1,662.5 million in 2012. Lorillard, NJOY and VMR products LLC are some of the major players in the e-cigarettes market.

Request for customization of this report http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1849

Geographically, North America dominates the global smoking cessation and nicotine de-addiction products market. The North American market for smoking cessation products was valued at USD 1,958.8 million in the year 2012. An increase in cigarette costs is expected to reduce smoking rates significantly, especially in adolescents. According to the CDC, a 10% rise in cigarettes cost can cut around 4% of young adults craving cigarette consumption. The European market held the second largest share worldwide, in 2012. WHO reports that European countries have widely adopted bans on tobacco advertising, promotion on national/international television and radio, billboards and outdoor advertising, local magazines and newspapers. However, some countries in Europe still lack in implementing measures of the WHO Framework Convention on Tobacco Control (FCTC).

Raising taxes to increase the cost of cigarettes can reduce tobacco use, cut smoking rates, and ultimately save lives. Smoking prevalence has been varying across the globe with many developing countries witnessing rapid increase in the prevalence rate, which will create huge health problems for the future if left unchecked. Demand for lifestyle drugs in emerging countries is witnessing rapid growth due to factors including growing health awareness, increase in population, and development of public healthcare systems, among others. This is driving people towards quitting smoking by adopting smoking cessation products. A study in the Eastern Mediterranean Health Journal, published in 2012, reported that nicotine containing medications are not available in one third of the developing countries, which include the Middle East and Africa. Moreover, accessibility of non-nicotine containing medications such as bupropion and varenicline is also extremely low. Increased attention and resources are needed to address lack of smoking cessation services as well as access to nicotine containing medications in these regions.

Browse all Press Releases: http://www.transparencymarketresearch.com/press-releases.htm

The global smoking cessation and nicotine de-addiction products market is segmented as follows

Smoking Cessation and Nicotine De-Addiction Products Market, by Product Type

Browse all Article : http://www.transparencymarketresearch.com/articles.htm

Nicotine Replacement Therapy Products

Nicotine Gums

Nicotine Transdermal Patches

Nicotine Lozenges

Nicotine Sprays

Nicotine Inhalers

Nicotine Sublingual Tablets

Drug Therapy

Zyban (bupropion)

Chantix/Champix (varenicline)

E-cigarettes

Smoking Cessation and Nicotine De-Addiction Products Market, by Geography

North America

Europe

Asia-Pacific

Rest of the World (RoW)

Browse all Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Sheela AK

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Web: http://www.transparencymarketresearch.com/

Blog: http://www.tmrblog.com/

Erectile Dysfunction Drugs Market Analysis 2013 - 2019

The global erectile dysfunction drugs market was valued at USD 4.3 billion in 2012 and is expected to decline at a CAGR of (4.5%) from 2013 to 2019, to reach an estimated value of USD 3.4 billion in 2019.

Browse the full report with complete TOC at Erectile Dysfunction Drugs Market http://www.transparencymarketresearch.com/erectile-dysfunction-drugs.html

Erectile dysfunction is the inability to attain or maintain penile erection in men, sufficient for successful sexual intercourse. Erectile dysfunction is a common medical disorder primarily affecting men older than 40 years of age. In addition, other than the typical causes of erectile dysfunction, such as diabetes and hypertension, a number of common lifestyle related factors are also associated with development of the condition. These include obesity, excessive alcohol consumption, smoking, use of recreational drugs, and poor physical and psychological health. Commonly, oral drugs belonging to the PDE 5 inhibitors class form the mainstay of erectile dysfunction treatment. Other treatment options include lifestyle modification, testosterone therapy, penile devices, injection therapies and psychotherapy.

The global market for erectile dysfunction drugs has been studied from the perspective of currently marketed branded drugs and pipeline drugs. Branded drugs include Viagra (sildenafil citrate), Cialis (tadalafil), Levitra/Staxyn (vardenafil), Stendra/Spedra (avanafil), Zydena (udenafil), MUSE (medicated urethral systems for erection), Mvix (mirodenafil) and Helleva (lodenafil). The drugs in the pipeline for erectile dysfunction treatment primarily consist of two major drugs, namely Vitaros (alprostadil) and Uprima (apomorphine) currently in later phases of clinical trials.

In 2012, Viagra (sildenafil citrate) accounted for the largest share (45%) by revenue of the total erectile dysfunction drugs market. However, due to the loss of the drug's patent exclusivity in Europe and other countries in 2013, the overall market revenue is expected to decline during the forecast period as international markets contribute considerably to the overall market revenue of the drug. In the U.S. market, Viagra will continue to maintain a major revenue share due to its extended patent exclusivity till 2020. The market for Cialis (tadalafil) accounted for the second largest share at USD 1,926.8 million, in 2012. However, it is expected to witness a decline in market revenue at a CAGR of (12.6%) from 2013 to 2019, owing to loss of patent exclusivity in 2017. In addition, the patent for Bayer's Levitra/Staxyn (vardenafil) is scheduled to expire in 2018 and is thus expected to contribute to the declining market revenue.

Request for customization of this report http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1550

A few novel compounds are currently under investigation in both preclinical and clinical settings, for the treatment of impotency. These studies are majorly focused on medications with improved efficacy, shorter onset of action and fewer side effects as compared to the currently available treatments. Such pipeline drugs include Vitaros (alprostadil), Uprima (apomorphine) and Topiglan (alprostadil), amongst others.

Geographically, North America dominated the global market for erectile dysfunction drugs in terms of revenue generation and is expected to maintain its position throughout the forecast period. The extended patent exclusivity for Pfizer's Viagra (sildenafil citrate) in the U.S., till 2020, will be responsible for the leadership of the North American market. Europe was the second largest regional market for erectile dysfunction drugs in 2012, owing to the increased demand for ED drugs. Market growth will also be facilitated by the expected marketing approvals for a few promising drug candidates such as Stendra/Spedra (avanafil) and Zydena (udenafil) by mid 2014.

Browse all Press Releases: http://www.transparencymarketresearch.com/press-releases.htm

The global erectile dysfunction dugs market is dominated by few major players including Pfizer, Inc. Eli Lilly & Co., and Bayer AG. Post patent expiration of the major branded drugs and intense genericization of the market, the competition in this market is expected to be characterized by consolidation activities, partnerships, and intensive mergers and acquisitions. The other key players in the erectile dysfunction drugs market include Dong-A Pharmaceutical Co. Ltd., Vivus, Inc., Apricus Biosciences, Inc. and Meda Pharmaceuticals.

Browse all Article : http://www.transparencymarketresearch.com/articles.htm

The global erectile dysfunction drugs market is segmented as follows:

Erectile Dysfunction Drugs Market, by Major Branded Products

Viagra

Cialis

Levitra/Staxyn

Stendra/Spedra

Zydena

MUSE

Mvix

Helleva

Erectile Dysfunction Drugs Market, Pipeline Analysis

Vitaros

Uprima

Others

Topiglan

Melanocortin Activators

Gene Therapy

Erectile Dysfunction Drugs Market, by Geography

North America

Europe

Asia-Pacific

Rest of the World (RoW)

Browse all Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Sheela AK

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Web: http://www.transparencymarketresearch.com/

Blog: http://www.tmrblog.com/

Global Biological Drugs Market is Expected to Reach USD 287,139.7 Million in 2020

The global biological drugs market is estimated at USD 161,056.5 million in 2014 and is expected to grow at a CAGR of 10.1% from 2014 to 2020, to reach an estimated value of USD 287,139.7 million in 2020.

Browse the full Biological Drugs Market Report at http://www.transparencymarketresearch.com/biological-drugs-market.html

The biological drugs market is witnessing a significant growth due to the increasing prevalence of chronic diseases and increase in the global geriatric population. Biological drugs are used in treatment and prevention of various diseases such as cancer, blood-related diseases, auto-immune diseases and other medical disorders. Moreover, various government associations are also promoting the usage of biological drugs. Furthermore, advancement in biomedical sciences holds immense potential for the growth of the biologic drugs market.

On the other hand, high cost of biological drugs and patent expiry of blockbuster drugs impede the growth of the market. Moreover, the risk of adverse effects associated with biologic injectable drugs is also one of the key restraints of the market. As a result, biological drugs market is expected to grow a CAGR of about 10.1% during 2014-2020.

Browse Press Release of Biological Drugs Market @ http://www.transparencymarketresearch.com/pressrelease/biological-drugs-market.htm

North America is the largest market for biological drugs. Increased use of biological drugs for the treatment of diseases such as cancer, diabetes and other chronic diseases are supporting the growth of the biological drugs market in the region. The American Center for Biological Medicine (ACBM) is one of the largest biological medicine clinics in the U.S.

Similarly, the European biological drugs market is growing rapidly due to increased usage of biological drugs for the treatment of various chronic diseases such as diabetes, cancer and inflammatory diseases.

In Asia, low manufacturing cost is attracting many biological manufactures to invest in Asian countries, supporting the growth of the biological drugs market. Moreover, Asian governments are also supporting growth of the biological drugs market by increased investment on biotech companies for construction of R&D and manufacturing facilities.

Request for customization of this report http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1694

Novartis AG, Pfizer Inc., GlaxoSmithKline plc. and Merck & Co., Inc. are the some of the leading players in the global biological drugs market. Other major players of biological drugs market include Abbott Laboratories, Biogen Idec and Amgen Inc.

The global market of biological drugs is segmented as follows:

Browse all Press Releases: http://www.transparencymarketresearch.com/press-releases.htm

Biological Drugs Market, By Therapeutic Protein

Enbrel

Lantus

Neulasta

Avonex

NovoLog

Rebif

Humalog

Aranesp

Epogen

Levemir

Victoza

Betaseron

Neupogen

Eylea

Browse all Article : http://www.transparencymarketresearch.com/articles.htm

Biological Drugs Market, By Monoclonal Antibody (mAb)

Humira

Remicade

Rituxan

Avastin

Herceptin

Lucentis

Biological Drugs Market, By Vaccine

Prenvar 13

Gardasil

Fluzone

Varivax

Cervarix

Biological Drugs Market, by Geography

North America

Europe

Asia

Rest of the World (RoW)

Browse All Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Ms. Sheela AK

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/

Company Blog: http://www.tmrblog.com/